COMMUNIQUÉS West-GlobeNewswire

AIM ImmunoTech Announces $2.4 Million Financing, Including Concurrent Registered Direct Offering and Private Placement
20/05/2026
OCALA, Fla., May 20, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc . (NYSE American: AIM) (“AIM” or the “Company”, today announced that it has entered into definitive agreements for a registered direct offering priced at- [...]
Ronald McDonald House New England Launches Brand Revitalization, Deepening its Mission to Keep Families Close
20/05/2026
Alongside a national brand modernization effort, Ronald McDonald House New England is preparing to embark on a bold new chapter—one that will meaningfully expand their ability to support families navigating pediatric [...]
How To Boost Testosterone After 40?| Safe Testosterone Boosters for Men Over 40 and 50 For Muscle Growth, Energy, Stamina and Performance in 2026 – Launched By Testoprime
20/05/2026
Testo Prime Launched Safe and Natural Testosterone Boosters for Men Over 40 and 50 For Muscle Growth, Read User Guide to Best Result For Energy, Stamina and Performance New York City, May 20, 2026 (GLOBE NEWSWIRE) -- IN [...]
MiNK Therapeutics Reports New Data on agenT-797, an allo-iNKT Cell Therapy at ATS 2026; Simultaneously Published in Clinical Immunology Communications
20/05/2026
agenT-797 demonstrates pathogen suppression, lung immune restoration and tissue repair activation, supporting Ongoing Phase 2 trial Sequential immunotherapy with agenT-797 and N-803, an FDA-approved IL-15 superagonist, [...]
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business Update
20/05/2026
IMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its trial in difficult-to-treat rheumatoid arthritis (D2T RA); Immunovant will [...]
Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026
20/05/2026
IMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its trial in difficult-to-treat rheumatoid arthritis (D2T RA); Immunovant will [...]
BlossomHill Therapeutics Expands Board of Directors with the Appointments of Sheila Gujrathi, M.D., and John Schmid
20/05/2026
Seasoned biopharmaceutical leaders bring significant clinical development, financial and strategic expertise to support BlossomHill's next phase of growth SAN DIEGO, May 20, 2026 (GLOBE NEWSWIRE) -- BlossomHill [...]
C4 Therapeutics to Participate in Upcoming Conferences
20/05/2026
WATERTOWN, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science, today [...]
Ichnos Glenmark Innovation (IGI) Announces New Development Candidate, ISB 2301, a First-in-Class Multispecific Immune Cells Activator Targeting Solid Tumors
20/05/2026
Next-generation multispecific antibody, ISB 2301, targets 3 tumor-associated antigens (TAAs) and activates both T cells and natural killer (NK) cells IGI’s clinically validated BEAT ® platform enabled the development of [...]
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
20/05/2026
BOSTON, May 20, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that [...]
NetraMark to Present at the American Society of Clinical Psychopharmacology Annual Meeting
20/05/2026
Company to participate in plenary panel on artificial intelligence in psychiatry and present two scientific posters highlighting explainable AI applications in precision psychiatry TORONTO, May 20, 2026 (GLOBE NEWSWIRE [...]
Syndax Announces Participation in Upcoming Investor Conferences
20/05/2026
NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief [...]
Medline Inc. announces launch of secondary offering of Class A common stock
20/05/2026
NORTHFIELD, Ill., May 20, 2026 (GLOBE NEWSWIRE) -- Medline Inc. (Nasdaq: MDLN) (“Medline”) announced today that certain selling stockholders affiliated with Blackstone Inc., Hellman & Friedman LLC and a wholly owned [...]
Emergent BioSolutions to Participate in Upcoming Investor Conferences
20/05/2026
GAITHERSBURG, Md., May 20, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s senior management team will participate in the following investor conferences: [...]
Repligen Announces Publication of the Company’s 2025 Corporate Sustainability Report
20/05/2026
WALTHAM, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the digital publication of its 2025 Corporate [...]
Kraig Biocraft Laboratories Highlights Technical Breakthrough of Its Immortalized Silk Gland Cell Platform
20/05/2026
ANN ARBOR, Mich., May 20, 2026 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company", "Kraig Labs", or "Kraig's"), a world leader in spider silk technology*, today announced additional [...]
Jupiter Neurosciences Secures $100M Term Sheet for Exclusive U.S. Rights to ALA-002, a Next-Generation MDMA Therapeutic from PharmAla Biotech
20/05/2026
Transaction Positions JUNS at the Forefront of Next-Generation MDMA-Based Therapeutics Following President Trump's April 18, 2026, Executive Order Accelerating Psychedelic Medicine JUPITER, FL, May 20, 2026 (GLOBE [...]
Lung Health Foundation Says Canada’s Current Access System to Emerging Therapies is Moving Slower than Modern Medicine
20/05/2026
New lung cancer and respiratory treatments are being developed faster than critically ill Canadian patients can access them, even when doctors believe they could help save lives; Canada’s largest charity dedicated to [...]
Dyne Therapeutics Announces Initiation of Phase 3 FORZETTO Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) Ahead of Planned BLA Submission for U.S. Accelerated Approval
20/05/2026
- 72-week trial will enroll approximately 90 participants; first site now open for enrollment - - Primary endpoint is rise from floor (RFF) velocity with multiple secondary endpoints to assess muscle and pulmonary [...]

Pages